Repron Therapeutics is developing a platform that utilizes engineered synthetic factors to silence transcriptional oncogenes in solid tumors, particularly in cases where surgical removal is not possible. This technology targets residual tumor cells and micro-metastases, aiming to reduce the risk of recurrence and metastasis in patients with epigenetic silencing regulations.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors cannot be completely removed surgically, leaving residual tumor cells and micro-metastases that can lead to recurrence and metastasis. Current cancer treatments often fail to address the underlying epigenetic dysregulation that drives oncogene expression in these residual cells.
Solution
Repron Therapeutics is developing a platform that uses engineered synthetic factors to selectively silence transcriptional oncogenes in solid tumors. This approach targets the epigenetic mechanisms that drive cancer progression, aiming to repress the expression of oncogenes in residual tumor cells and micro-metastases. By silencing these oncogenes, Repron's technology seeks to reduce the risk of tumor recurrence and metastasis, particularly in patients where surgical removal is not a viable option. The platform offers a novel therapeutic strategy by directly addressing the epigenetic drivers of cancer.
Target Audience
The primary target audience includes patients with solid tumors where complete surgical removal is not possible, as well as oncologists and researchers focused on epigenetic regulation in cancer.
Features
- Engineered synthetic factors designed to selectively target and silence transcriptional oncogenes.
- Platform focused on epigenetic silencing regulations within tumor cells.
- Therapeutic approach targeting residual tumor cells and micro-metastases post-surgery.
- Aims to reduce the risk of tumor recurrence and metastasis.